The Study Of Fluconazole For Vulvovaginal Candidiasis
Status:
Completed
Trial end date:
2013-11-22
Target enrollment:
Participant gender:
Summary
As for the indication of vulvovaginal candidiasis, a single oral administration of
fluconazole 150 mg has been approved and is recommended by guidelines overseas. However in
Japan oral therapy with antifungal triazole such as Fluconazole has not been approved, and
topical therapies such as vaginal tablets, pessary and cream are used clinically. The purpose
of this trial is to confirm the efficacy and safety of single oral administration of
fluconazole 150 mg for the treatment of vulvovaginal candidiasis in Japanese patients.